KEDI Global Longevity Bio Index

Johnson & Johnson is scheduled to report third-quarter 2026 results on October 13, 2026, with published consensus EPS estimates of approximately $3.02-$3.04.

Novo Nordisk is scheduled to hold its Capital Markets Day in London on 21 September 2026.

The FDA is expected to decide on Regeneron’s priority-reviewed garetosmab BLA for adults with fibrodysplasia ossificans progressiva in August 2026, with catalyst calendars listing August 19.

The FDA is scheduled to decide on Bristol Myers Squibb's NDA for iberdomide with daratumumab and dexamethasone in relapsed or refractory multiple myeloma on August 17, 2026.

Roivant is expected to report first-quarter fiscal 2027 financial results before market open on August 10, 2026.

Natera is estimated to report second-quarter 2026 results on August 6, 2026, with consensus EPS estimates around a loss of $0.51 to $0.52.

Viatris is scheduled to report second-quarter 2026 financial results on August 6, 2026, with third-party consensus EPS estimates of approximately $0.61.

Eli Lilly will announce second-quarter 2026 financial results and hold its earnings call on August 5, 2026.

The FDA is scheduled to issue its PDUFA decision on Moderna's mRNA-1010 seasonal influenza vaccine on August 5, 2026.

Novo Nordisk is scheduled to announce its first-half 2026 financial results on 5 August 2026 at 07:30 CEST.

Amgen has officially scheduled its Q2 2026 earnings conference call for August 4, 2026 at 1:30 p.m. PDT, following the U.S. market close.

Gilead is scheduled to release second-quarter 2026 financial results and guidance after the market closes on August 4, 2026.

Merck is scheduled to release second-quarter 2026 sales and earnings and hold its investor conference call on August 4, 2026.

Pfizer is scheduled to issue its Second Quarter 2026 Performance Report on the morning of August 4, 2026.

Merck is scheduled to hold a virtual HIV Investor Event on August 3, 2026, at which senior management will update investors on the company’s HIV program and strategy.

AbbVie is scheduled to release second-quarter 2026 financial results before the U.S. market opens on July 31, 2026, followed by an 8:00 a.m. CDT earnings webcast.

Moderna is scheduled to report second-quarter 2026 financial results and hold its Q2 earnings call at 8:00 a.m. ET on July 31, 2026.

Alnylam is scheduled to report second-quarter 2026 financial results before U.S. market open on July 30, 2026.

Bristol Myers Squibb is scheduled to report second-quarter 2026 financial results on July 30, 2026.

Illumina is scheduled to release second-quarter 2026 financial results after market close on July 30, 2026, followed by an investor and analyst conference call.

Regeneron is scheduled to report second-quarter 2026 financial and operating results before U.S. market open on July 30, 2026.

Sanofi is scheduled to publish its second-quarter 2026 financial results on July 30, 2026.

Takeda is scheduled to release FY2026 first-quarter results and host an investor, analyst and media webcast on July 30, 2026.

The FDA PDUFA goal date for Viatris' investigational low-dose estrogen combined hormonal contraceptive weekly patch is July 30, 2026.

ICON formally announced that it will release second-quarter 2026 financial results after the U.S. market closes on July 29, 2026, followed by a conference call on July 30.

Biogen is scheduled to report second-quarter 2026 financial results before U.S. markets open on July 29, 2026.

Ionis is scheduled to report second-quarter 2026 financial results and host a webcast on July 29, 2026.

Teva is scheduled to release second-quarter 2026 financial results at 7:00 a.m. ET on July 29, 2026, followed by an 8:00 a.m. ET conference call and webcast.

GSK is scheduled to announce its second-quarter 2026 results and a portfolio-growth update on 28 July 2026.

IQVIA is scheduled to report second-quarter 2026 financial results before market open on July 28, 2026.

AstraZeneca is scheduled to publish its H1 and Q2 2026 financial results before market open on 27 July 2026.

Johnson & Johnson reported positive Phase 3 MonumenTAL-6 topline results for TECVAYLI plus TALVEY in earlier-line relapsed or refractory multiple myeloma.

Eli Lilly reported positive Phase 3 TRIUMPH-2 and TRIUMPH-3 topline results for investigational obesity drug retatrutide and plans an FDA BLA submission in the first quarter of 2027.

RELX reported H1 2026 underlying revenue growth of 7%, adjusted operating-profit growth of 9%, and reaffirmed its full-year outlook for strong underlying growth.

Thermo Fisher reported second-quarter 2026 revenue of $11.99 billion and adjusted EPS of $6.03, and raised its full-year outlook.

Thermo Fisher indicated on its second-quarter 2026 earnings call that the previously announced sale of its microbiology business to Astorg is expected in the third quarter of 2026.

The FDA approved GSK's Jideytro (zidesamtinib) for adults with previously treated locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Arrowhead reported positive topline Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia on July 22, 2026.

Johnson & Johnson received FDA De Novo authorization for the OTTAVA robotic surgical system in the United States.

Medpace raised its 2026 revenue outlook to $2.805-$2.885 billion and GAAP diluted EPS outlook to $17.25-$17.95 alongside its second-quarter results.

The FDA accepted Pfizer's TALZENNA plus XTANDI supplemental application for Priority Review in HRR gene-altered metastatic castration-sensitive prostate cancer.

China's NMPA approved Takeda's ORZEYFUL (oveporexton) for narcolepsy type 1 in patients aged 16 years and older.

Gilead and Merck announced detailed 48-week Phase 3 results showing once-weekly islatravir/lenacapavir maintained virologic suppression in the ISLEND-1 and ISLEND-2 trials.

Gilead reported 52-week open-label-extension data from PURPOSE 1 and PURPOSE 2 showing sustained efficacy, high adherence, and no new safety signals for twice-yearly lenacapavir PrEP.

Merck and Gilead reported that once-weekly oral islatravir/lenacapavir maintained virologic suppression at Week 48 in both Phase 3 ISLEND trials.

Novartis confirmed that a BLA for accelerated approval of del-zota in Duchenne muscular dystrophy amenable to exon 44 skipping was submitted to the FDA.

Novartis reported clinically meaningful six-year overall-survival data for Kisqali in early breast cancer and said the FDA granted six months of pediatric exclusivity across its Orange Book-listed patents.

Novartis said it completed US and EU submissions for traditional approval of Vanrafia in adults with primary IgA nephropathy.

Novartis reported Q2 2026 core EPS of $2.41 and net sales of $14.41 billion, exceeding consensus estimates and reaffirming full-year guidance.

Novo Nordisk’s false-advertising lawsuit against Eli Lilly was updated by Lilly’s public statement that it will defend the case vigorously.

Sanofi announced a revised Executive Committee on July 21, 2026, with the new structure scheduled to take effect on September 1, 2026.

Following Indian marketing authorization for Qdenga, Takeda expects initial availability through private healthcare settings in the first half of 2027.

The EMA accepted GSK’s submission to add a single Bexsero meningitis-B booster for previously vaccinated individuals aged 10 years and older.

Mike Sullivan assumed the Chief Commercial Officer role at Illumina on July 20, 2026, completing the first of the two previously announced executive appointments.